NCT06228781Not yet recruiting
Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission. Over the past two decades, aHSCT has been used to treat inflammatory autoimmune disease of the CNS. Patients with relapsing-remitting multiple sclerosis benefit from aHSCT treatment. However, a certain percentage of patients still experience recurrence 3 or 5 years after transplantation. Therefore, exploration of conditioning regimens will drive therapeutic advances in aHSCT in autoimmune diseases of the CNS.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 19 Jan 2024
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Jan 2029
- Lead sponsor
- Tianjin Medical University General Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT06228781
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Dec 2026 to the primary completion date, 1 Jan 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients having received a cytotoxic agent within one month of enrolling in this study;
- Patients having received a cytotoxic agent within one month of enrolling in this study;
Other illness
- Patients with evidence of myelodysplasia or other non-autoimmune cytopenia;
- Patient with any active or chronic infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, EB virus, human immunodeficiency virus, hepatitis virus, syphilis, etc.);
- Patients with a malignant tumor currently or within the last 5 years;
- Patients with cardiac, renal, pulmonary, hepatic or other organ impairment;
- Patients whose life expectancy is severely limited by another conditions;
Other
- Pregnancy or risk of pregnancy;
- Patients unable to give written informed consent in accordance with research ethics board guidelines.
Who the study is looking for
- Age 18-60 years;
- Diagnosed multiple sclerosis with relapses or progression and sustained accumulated impairment by a neurologist expert in the field;
- EDSS score of 3-6 (including 3 and 6);
- EDSS cerebellar functional score ≥ 3 or EDSS pyramidal functional score ≥3；
- Evidence of current disease activity;
- If a patient has previously received a cytotoxic agent (mitoxantrone, cyclophosphamide etc.) they must have normal bone marrow morphology and cytogenetics before being considered eligible for this study ;
- No evidence of hepatic inflammation or fibrosis;
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.